Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Centocor: Show Me The REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.
Advertisement

Related Content

Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Stelara Clears FDA; Different Mechanism of Action, But REMS Looks Similar To TNF Class
Opioid Class REMS: FDA Wants Prescriber/Pharmacist Certification
J&J Advances Pipeline With Yondelis, Carisbamate Filings
Johnson & Johnson Push Ahead With Invega Franchise
J&J Advances Pipeline With Yondelis, Carisbamate Filings
FDA Holds Up Centocor’s Ustekinumab Three Months But Wants No New Trials
FDA Panel Recommends Centocor’s Ustekinumab Approval; Questions Dosing
FDA Panel Recommends Centocor’s Ustekinumab Approval; Questions Dosing

Topics

Advertisement
UsernamePublicRestriction

Register

PS067158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel